Mid-Year Market Review and Outlook
This review of the first half of 2014 is an expert analysis that examines the implications behind the dramatic increase in funding for smaller companies, and identifies global bio/pharma companies that are driving R&D and sales.
The report includes an analysis of small molecule development, and how it continues to outpace large molecules—at least for venture capital-backed companies.
Who should buy this report?
This report is required reading for:
• CMO executives
• Bio/pharmaceutical sourcing and procurement executives
• Private equity investors
*This report will be available the first week in November 2014.
Yes! Please contact me with pricing information and more details when this Trend Report becomes available.
Please submit your contact information below and a representative will be in touch with you soon:
You can also find out more by contacting us at firstname.lastname@example.org /+ 1-703-383-4903, ext. 101 (ET USA).